REG - Yourgene Health PLC - Directorate Change

Yourgene HealthAnnouncement

25/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230125:nRSY7443Na&default-theme=true

RNS Number : 7443N  Yourgene Health PLC  25 January 2023

Yourgene Health plc

("Yourgene", the "Group" or the "Company")

 

Directorate Change

 

Manchester, UK - 25 January 2023: Yourgene (AIM: YGEN), a leading
international molecular diagnostic group, announces that further to the
announcement made on the 21 December 2022 regarding the evolution of the
Board, Andrew ("Andy") Leeser has been appointed as a Non-executive Director
("NED") with immediate effect.

 

Andy is one of the UK's most experienced mid-market corporate transformation
specialists. He has been involved with a range of transformation projects and
transactions, including refinancings and equity/ asset sales across the
Automotive, Oil and Gas, Brewing, Retail and Telecommunications sectors.
Recent examples of businesses he has supported include Sepura plc, Sterling
Resources (SRUK) and OEG Offshore (Northstar Holding Ltd). He was also part of
the team which, in cooperation with HMG, closed the English deep mine coal
industry in a controlled manner. Andy is the current Chairman of the Institute
for Turnaround (the "IFT").

 

Dr John Brown CBE, Non-executive Chairman, commented: "I am delighted to
welcome Andy to the Yourgene Board. I'm sure his breadth of experience will
bring new perspectives and make a significant contribution to the future
success of the Company."

 

Further disclosures on Andy Leeser as required under Schedule Two, paragraph
(g) (i)-(viii) of the AIM Rules for Companies are included in the appendix
below.

 

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 

 Yourgene Health plc                                                         Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                                           investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)                                        Tel: +44 (0)20 7213 0880
 Liam Murray / Ludovico Lazzaretti

 Singer Capital Markets (Corporate Broker)                                   Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
                                                 (mailto:yourgene@walbrookpr.com)
 Paul McManus / Alice Woodings / Lianne Applegarth                           Mob: 07980 541 893 / 07407 804 654/ 07584 391 303

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling precision medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

Appendix

 

Disclosures in accordance with the AIM Rules

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Andrew John Leeser (aged 64):

 

 Current appointments                   Former appointments in the last 5 years
 Corporate Development Partnership Ltd  Extentia Group Limited(3)
 Institute For Turnaround               Northstar Holding Limited
 Palmer & Harvey (Holdings) PLC(1)      One-Dyas UK Limited
 Palmer & Harvey McLane Limited(2)      Sepura Limited
 Sigma Voice Solutions Ltd              SRUK Holdings Ltd
                                        The GDM Group Limited
                                        UK Coal Mining Holdings Limited(4)
                                        UK Coal Production Limited(5)

 

 

(1)Palmer & Harvey (Holdings) PLC entered into administration on 29
November 2017. Andy was appointed as a director of the company on 13 April
2017 and the administration process is ongoing.

 

(2)Palmer & Harvey McLane Limited entered into administration on 28
November 2017. Andy was appointed as a director of the company on 13 April
2017 and the administration process is ongoing.

 

(3)Extentia Group Limited entered into administration on 28 February 2020.
Andy resigned as a director 13 January 2020 and the administration process is
ongoing.

 

(4)Andy was previously a director of UK Coal Mining Holdings Limited
("UKCMHL") and its wholly owned subsidiary (5)UK Coal Production Limited
("UKCPL") from 25 September 2014 to 24 April 2020 (to 27 December 2019 for
UKCPL). The group conducted a managed closure plan and UKCPL was placed into
liquidation via a creditor's voluntary liquidation on 17 May 2016 and then
UKCMHL was placed into liquidation via a creditor's voluntary liquidation on
19 August 2016. Approximately £61m was outstanding to secured creditors as a
result of this managed closure plan.  UKCPL was dissolved on 27 December 2019
and UKCMHL was dissolved on 24 April 2020 with no material unsecured creditors
affected.

 

Andy was previously and temporarily a director of Privet H Limited from 11
February 2011 to 25 February 2011 after which he had no involvement with the
company. The company was placed into liquidation via a creditor's voluntary
liquidation on 5 December 2011. Approximately £19m was outstanding to
creditors when the company was dissolved on 16 August 2013.

 

Andy Leeser, does not hold any shares or options over ordinary shares in the
Company.

 

There are no further disclosures required in accordance with AIM Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGZGZMRDZGFZM